Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Changes in incidence and epidemiology of antimicrobial resistant pathogens before and during the COVID-19 pandemic in Germany, 2015-2022.
BMC Microbiol
January 2025
Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany.
Background: Carbapenem-resistant Gram-negative bacteria and methicillin-resistant Staphylococcus aureus (MRSA) are among WHO's priority pathogens with antimicrobial resistance (AMR). Studies suggest potential impacts of the COVID-19-pandemic on AMR. We described changes in AMR incidence and epidemiology in Germany during the COVID-19-pandemic.
View Article and Find Full Text PDFEpidemiology of invasive Haemophilus influenzae infections in Belgium: 2018-2022.
Eur J Clin Microbiol Infect Dis
January 2025
National reference centre for Haemophilus influenzae, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium.
Introduction: Haemophilus influenzae plays a major role in invasive bacterial infections. Resistant strains are emerging, prompting the WHO to include H. influenzae on its list of priority pathogens for research and development of new antibiotics.
View Article and Find Full Text PDFAssociation between Delayed Broad-Spectrum Gram-negative Antibiotics and Clinical Outcomes: How Much Does Getting It Right with Empiric Antibiotics Matter?
Clin Infect Dis
January 2025
Department of Epidemiology and Public Health, University of Maryland School of Maryland; Baltimore, MD.
Background: Clinicians often start unnecessarily broad-spectrum empiric Gram-negative antibiotics out of the concern that delaying effective therapy could lead to a worse clinical outcome. This study examined the consequences of delayed initiation of broad-spectrum Gram-negative antibiotics.
Methods: In a retrospective cohort of adult inpatients from 928 US hospitals, we compared clinical outcomes after (1) empiric narrow-spectrum antibiotics escalated to broad-spectrum antibiotics (delayed broad-spectrum therapy, DBT) and (2) empiric broad-spectrum antibiotics continued for at least 5 days (early broad-spectrum therapy, EBT) using Win Ratios.
Current advances and challenges in mpox vaccine development: a global landscape.
Ther Adv Vaccines Immunother
January 2025
Virology Department of Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Given the surge in mpox outbreaks in 2022 and the advancements in domestic and international vaccine research, the effectiveness of smallpox vaccines in providing cross-protection against mpox remains crucial. Having learned from the COVID-19 pandemic, it is significant to continue evaluating existing vaccines to ensure their safety and efficacy. Developing new vaccines for widespread use against mpox and its emerging strains also serves as a preventive strategy in the ongoing battle against this dynamic infection.
View Article and Find Full Text PDFThe history of the Croatian pharmaceutical company PLIVA from the very beginning to the status of a recognisable European and global player is described. Special attention is paid to PLIVA's cooperation with the Croatian Nobel laureate Vladimir Prelog and the invention of the proprietary antibiotic azithromycin. The antibiotic was commercialised in cooperation with the US-based company Pfizer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!